Andrew Huberman said the MDMA therapy setback was about bad science and weak safeguards, not MDMA itself. Speaking on The Joe Rogan Experience, he said the FDA's last review of MDMA-assisted psychotherapy for PTSD failed to pass, even though the treatment had shown a 60, 70% significant reduction in symptoms in some cases remission.
Huberman also said there is no evidence that MDMA is neurotoxic. He pointed to a study published in Science on non-human primates that was later retracted because the laboratory accidentally injected methamphetamine, not MDMA.
Joe Rogan and MDMA dosing
Huberman said he was "very close to this whole situation" and described a protocol built around body-weight-scaled doses of roughly 80 milligrams with a 50-milligram booster. He said the sessions were spaced about three weeks apart and included talk therapy before, during, and after the sessions.
That structure matters because Huberman said psychedelic-assisted therapy still lacks formalized standards for what happens during a session. He said the first step in trauma resolution is willingness, and the second is experiencing the painful feeling in a safe environment.
FDA review and therapist conduct
Huberman said regulators identified an inadequate control or placebo condition and one or two sexual improprieties by the therapist. He said, "One incident like that can sink an entire initiative."
He also said the review failed because the session design gave too much room for bias, adding that in that setting, "every idea is a good idea and everything's about them and their goals."
Subsequent round
Huberman said the MDMA therapy submission may pass in a subsequent round if safeguards are put in place to ensure safe administration. He drew a contrast with psilocybin, which he said may require only a single session, while MDMA therapy depends on repeated visits and tighter rules for what happens between the drug and the patient.
The practical issue for people seeking MDMA-assisted psychotherapy for PTSD is not whether the drug can produce symptom relief, but whether a future submission can show a controlled session format that keeps therapists within clear limits. Huberman said that standard does not yet exist, and he tied the next step to putting those safeguards in place.
